Transgene

Transgene Equity Ratio

The Equity Ratio of Transgene (TNG.PA) as of Nov 18, 2026 is 36.05 %. In the previous year, Equity Ratio was 34.53 % — a change of 4.41% (higher).

Equity Ratio

36.05 %

YoY

4.41%

Last updated:

Equity Ratio of Transgene is 2024 36.05 % . Equity Ratio of Transgene was 2023 34.53 % . It decreases by 4.41% higher compared to the previous year.

The Transgene Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2017
27.85 EUR
Jan 1, 2018
33.78 EUR
Jan 1, 2019
56.89 EUR
Jan 1, 2020
58.80 EUR
Jan 1, 2021
66.00 EUR
Jan 1, 2022
56.96 EUR
Jan 1, 2023
34.53 EUR
Jan 1, 2024
36.05 EUR
The Transgene Equity Ratio history
YEAREquity RatioYoY
36.05 %+4.41%
34.53 %-39.38%
56.96 %-13.69%
66.00 %+12.23%
58.80 %+3.36%
56.89 %+68.43%
33.78 %+21.30%
27.85 %-26.38%
37.82 %+43.71%
26.32 %-48.36%
50.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Equity Ratio of Transgene is 36.05 % in 2024.

Equity Ratio of Transgene changed from 34.53 % to 36.05 %, representing a 4.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Transgene since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Transgene

All Key Metrics — Transgene